Tildrakizumab
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Tildrakizumab |
| Trade Name | Ilumya |
| Synonyms | MK-3222 |
| Drug Descriptions |
Ilumya (tildrakizumab) is a monoclonal antibody that binds to the p19 subunit of IL-23 and prevents interaction with the IL-23 receptor, potentially leading to decreased release of proinflammatory cytokines (PMID: 31548750). Ilumya (tildrakizumab) is FDA approved for use in patients with moderate-to-severe plaque psoriasis (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 1326244-10-3 |
| NCIT ID | C152627 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Abiraterone + Tildrakizumab | Abiraterone Tildrakizumab | 0 | 1 |
| Tildrakizumab | Tildrakizumab | 0 | 0 |
CKB BOOST